Canada & Sunshine Biopharma

Canada: Canada is the market where Sunshine Biopharma's generic Rivaroxaban tablets received approval, contributing to the Canadian pharmaceutical market.

Sunshine Biopharma: Sunshine Biopharma received approval for its generic Rivaroxaban tablets in Canada, expanding its portfolio of anticoagulant drugs and strengthening its position in the generics market.

Canada: Canada is the market where Sunshine Biopharma received regulatory approval for its generic Anastrozole tablets, representing a significant market for the company's expansion.

Sunshine Biopharma: Sunshine Biopharma received Canadian regulatory approval for its generic Anastrozole tablets, expanding its portfolio in breast cancer therapy and strengthening its position in the generics market. This approval is expected to contribute to its financial growth.

Sunshine Biopharma: Sunshine Biopharma successfully closed a public offering, raising $6 million in gross proceeds with potential for an additional $12 million from warrant exercises, which will be used for general corporate purposes and working capital. This financing is substantial relative to its market capitalization and addresses its negative free cash flow.